Literature DB >> 8835572

Antinuclear antibodies in children with localized scleroderma.

A M Rosenberg1, Y Uziel, B R Krafchik, S A Hauta, P A Prokopchuk, E D Silverman, R M Laxer.   

Abstract

OBJECTIVE: To determine the prevalence and antigenic specificities of antinuclear antibodies (ANA) in children with localized scleroderma.
METHODS: The ANA profiles of 27 children with localized scleroderma were determined. The study group comprised 21 children with linear scleroderma, 5 with morphea, and 1 with combined linear scleroderma and morphea. Sera were evaluated for the presence of ANA by indirect immunofluorescence and for reactivity with specific nuclear antigens by ELISA and immunoblotting.
RESULTS: Seventeen patients (63%) had positive tests for ANA. Of these sera 10 displayed a finely speckled pattern, 5 a combined nucleolar and finely speckled nuclear pattern, and 2 a nucleolar pattern only. Fourteen of 21 (67%) with linear scleroderma were ANA positive. Three of 5 patients with morphea (60%) had ANA. The 1 patient with both linear scleroderma and morphea was ANA negative. Fifteen sera (56%) contained antibodies to denatured DNA (dDNA). Eleven sera (41%) had antibodies to one or more high mobility group (HMG) proteins, 4 (15%) reacted with one or more histones and 1 serum (4%) reacted with topoisomerase I (Sc1-70).
CONCLUSION: ANA are present in most children with localized scleroderma and frequently have specificity for dDNA and HMG proteins. Children with localized scleroderma, like patients with systemic sclerosis (SSc), commonly have ANA and antibodies to dDNA. Unlike patients with SSc, however, childhood localized scleroderma is uncommonly associated with antibodies to certain specific nuclear and nucleolar constituents that typically occur in association with SSc.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835572

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Frequency of antinuclear antibodies in mestizo Mexican children with morphea.

Authors:  Elizabeth Guevara-Gutiérrez; Janeth Yinh-Lao; Patricia García-Gutiérrez; Alberto Tlacuilo-Parra
Journal:  Clin Rheumatol       Date:  2010-06-14       Impact factor: 2.980

Review 2.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

5.  Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases.

Authors:  Justin J Leitenberger; Rachael L Cayce; Robert W Haley; Beverley Adams-Huet; Paul R Bergstresser; Heidi T Jacobe
Journal:  Arch Dermatol       Date:  2009-05

6.  Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea.

Authors:  Jennifer Warner Dharamsi; Sandra Victor; Nancy Aguwa; Chul Ahn; Frank Arnett; Maureen D Mayes; Heidi Jacobe
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

7.  Pansclerotic morphea: A male child with hemiatrophy of lower limb.

Authors:  Malay K Dasgupta; Chaitali Patra; Shatanik Sarkar; Sabyasachi Das
Journal:  Indian Dermatol Online J       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.